Windtree’s Istaroxime Scores in Cardiogenic Shock Trial
CardiacWire
SEPTEMBER 25, 2024
Windtree Therapeutics’ istaroxime appears to have scored in its latest Phase 2b trial , showing that the steroidal drug significantly improves systolic blood pressure in cardiogenic shock patients. That could be a big deal in the cardiogenic shock space, which many believe is still in need of more effective treatments.
Let's personalize your content